Addyi Anesthesia and Perioperative Interaction: What Patients and Clinicians Need to Know

What Is Flibanserin and Why Does It Matter in the Operating Room?

Flibanserin is not a simple hormonal medication. It acts on the central nervous system through multiple receptor pathways, and those same pathways are targeted by nearly every drug used in a modern anesthetic. The FDA granted approval in August 2015 after two prior rejections, and the agency required a Risk Evaluation and Mitigation Strategy (REMS) specifically because of hypotension and syncope signals identified during clinical development. [1]

Mechanism of Action

Flibanserin acts as a full agonist at serotonin 1A (5-HT1A) receptors, an antagonist at serotonin 2A (5-HT2A) receptors, and a weak antagonist at dopamine D4 receptors in the prefrontal cortex. [2] This tri-receptor profile produces measurable sedation, dizziness, and blood pressure reduction even at the approved 100 mg nightly dose. In the key VIOLET and DAISY trials that supported FDA approval, somnolence occurred in 11 to 13% of women on flibanserin versus 2 to 3% on placebo, and dizziness occurred in 11% versus 2%. [1]

Pharmacokinetics Relevant to Anesthesia Planning

The elimination half-life averages 11 hours. At a nightly 100 mg dose, steady-state plasma concentrations are reached within five days. After the last dose, plasma levels fall to approximately 3% of Cmax by 48 hours. This PK profile informs the two-day washout recommendation. CYP3A4 is the dominant metabolic pathway; co-administration of the moderate CYP3A4 inhibitor fluconazole increased flibanserin AUC by 7-fold in a dedicated DDI study published in the FDA's pharmacology review. [1] Anesthesiologists using azole antifungals or macrolide antibiotics perioperatively must account for possible residual flibanserin accumulation if the washout was computed without considering inhibitor exposure. [3]

The Core Interaction: CNS Depression and Hypotension

The central danger of combining flibanserin with anesthetic agents is additive, and in some combinations possibly synergistic, CNS and cardiovascular depression. The FDA Black Box Warning states explicitly that hypotension and syncope risk increase substantially when flibanserin is taken with alcohol or other CNS depressants. [1]

Volatile Anesthetic Agents

Sevoflurane, desflurane, and isoflurane all produce dose-dependent CNS depression and vasodilation. Flibanserin's 5-HT1A agonism independently reduces sympathetic outflow, lowering peripheral vascular resistance. Combining the two mechanisms may produce exaggerated mean arterial pressure drops. No prospective clinical trial has quantified the magnitude of interaction with a specific volatile agent, but the pharmacodynamic rationale is well-established in receptor-level studies of 5-HT1A agonism and cardiovascular regulation. [4] Anesthesiologists should anticipate a lower inhalational MAC requirement and prepare vasopressor support.

Propofol and IV Induction Agents

Propofol acts through GABA-A receptor potentiation and produces hypotension at induction doses averaging 1.5 to 2.5 mg/kg in unpremedicated adults. [5] A patient with residual flibanserin on board presents with already-reduced vascular tone. The combination may necessitate reduced propofol induction doses, a slower infusion rate, or pre-emptive phenylephrine boluses. Ketamine's sympathomimetic offset partially mitigates hypotension risk and may be a preferred induction agent when flibanserin has not been fully washed out.

Opioids

Opioids suppress central sympathetic tone and produce dose-dependent hypotension, particularly in volume-depleted or elderly patients. [6] Flibanserin's dopaminergic activity in the prefrontal cortex may amplify opioid-induced sedation through converging CNS pathways. The FDA label explicitly lists opioids as drugs that increase the risk of hypotension and CNS depression when combined with flibanserin. [1] In a pharmacokinetic interaction study, a single oral dose of alcohol 0.4 g/kg combined with a single 100 mg flibanserin dose produced orthostatic hypotension in 4 of 6 women tested, with two experiencing syncope. [1] Opioids produce comparable vasodilation, making the risk profile analogous.

Benzodiazepines and Sedative Premedications

Benzodiazepines potentiate GABA-A, which is mechanistically distinct from flibanserin's serotonergic pathway, yet both classes converge on respiratory depression and reduced consciousness. Midazolam 1 to 2 mg IV, a standard anxiolytic premedication, has been shown to potentiate hypotension from concurrent vasodilatory drugs in observational surgical series. [7] When flibanserin has not been discontinued pre-operatively, midazolam doses should be halved and titrated to effect.

Alcohol Interaction: The Black Box Warning in Detail

The alcohol interaction deserves specific attention because patients taking Addyi are counseled about it at every dispensing under REMS requirements, yet the mechanism directly informs perioperative risk.

What the Clinical Study Showed

The FDA-mandated alcohol interaction study enrolled 25 premenopausal women. Participants received flibanserin 100 mg with either 0.4 g/kg or 0.8 g/kg alcohol. At the 0.4 g/kg dose (approximately two standard drinks), hypotension severe enough to prompt intervention occurred in 4 of 25 participants; at 0.8 g/kg, 6 of 25 experienced hypotension and 2 experienced syncope. [1] Blood pressure nadirs were documented at 30 to 60 minutes post-ingestion, correlating with the Cmax of flibanserin.

Why This Matters for the Pre-op Period

A patient who takes her nightly flibanserin at 10 PM and has a 7 AM surgical start may present with plasma concentrations still above 20% of Cmax. If she consumed even a small amount of alcohol the evening before (a common pre-surgical anxiety behavior), she may already be experiencing residual hemodynamic lability before the first drug is administered. Pre-op nursing assessment should include direct questioning about flibanserin use, last dose timing, and any alcohol consumed within 12 hours.

Recommended Perioperative Management Protocol

The following framework synthesizes the FDA label, published anesthesiology pharmacology principles, and CYP3A4 interaction data into a clinical decision pathway for patients presenting for elective or semi-urgent surgery.

Step 1: Pre-operative Disclosure and Timing

Patients should disclose flibanserin use to their surgical team at the initial pre-operative assessment, not on the day of surgery. The FDA label recommends stopping flibanserin at least two days before elective surgery. [1] Given the 11-hour half-life, two days (48 hours) reduces plasma concentrations to roughly 3% of the last steady-state Cmax, which the FDA pharmacology reviewers considered a clinically acceptable residual level. [1]

For patients who have also been taking a CYP3A4 inhibitor (fluconazole, clarithromycin, diltiazem, grapefruit), the effective washout may need to extend to four to five days, because inhibitor-elevated flibanserin concentrations take longer to clear. Clinicians should verify the complete medication list, not just the flibanserin disclosure. [3]

Step 2: Intraoperative Hemodynamic Preparedness

When a patient discloses recent flibanserin use or when elective washout was not completed (urgent or emergent cases), the anesthesia team should:

• Establish arterial line monitoring for continuous blood pressure in high-risk cases.
• Pre-load with 500 mL isotonic crystalloid before induction if hemodynamically appropriate.
• Reduce propofol induction dose by 20 to 30% and titrate slowly.
• Have phenylephrine 100 mcg boluses or a norepinephrine infusion immediately available.
• Consider ketamine as the primary induction agent at 1 to 1.5 mg/kg in hemodynamically fragile patients. [5]

Step 3: Post-operative Monitoring

Residual anesthetic agents combined with unmetabolized flibanserin may delay the return of normal vascular tone in the post-anesthesia care unit (PACU). The standard PACU discharge criteria from the Aldrete scoring system require a blood pressure within 20 mmHg of baseline. [8] Patients with known flibanserin exposure should meet this criterion for at least 30 minutes before discharge from phase-I recovery. Orthostatic vital signs before ambulatory discharge are warranted.

Step 4: Resuming Flibanserin After Surgery

No specific FDA guidance exists on resumption timing. Given that most general anesthetics clear within 24 hours and opioid analgesics are typically tapered within the first 48 to 72 post-operative hours, resuming flibanserin after 48 hours post-operatively is a reasonable approach, contingent on hemodynamic stability. The prescribing physician and anesthesiologist should communicate this timeline explicitly in discharge instructions.

CYP3A4 Drug Interactions and Anesthetic Implications

Flibanserin is both a CYP3A4 substrate and a weak CYP3A4 inducer at high concentrations. [1] Several drugs used perioperatively interact via this pathway.

CYP3A4 Inhibitors Used Perioperatively

• Fluconazole: A single 200 mg dose increased flibanserin AUC by 7.0-fold in a dedicated DDI study. This combination is contraindicated in the flibanserin label. [1] Fluconazole is sometimes used perioperatively for Candida prophylaxis in immunocompromised surgical patients.
• Diltiazem: A calcium-channel blocker used for intraoperative rate control; classified as a moderate CYP3A4 inhibitor. Co-administration with flibanserin in a DDI study raised flibanserin AUC 2.4-fold. [1]
• Clarithromycin: Occasionally given perioperatively for atypical pneumonia coverage; a strong CYP3A4 inhibitor whose interaction with flibanserin is listed as contraindicated in the label. [1]

Enzyme-Inducing Anesthetic Adjuncts

Rifampin, sometimes used in orthopaedic implant infections, is a potent CYP3A4 inducer and reduces flibanserin AUC by 95%, effectively eliminating therapeutic plasma levels. [1] This interaction is relevant to the post-discharge period if antibiotics change.

Alcohol Avoidance During Addyi Therapy: Broader Context

The question "can I drink on Addyi" is among the most commonly searched queries related to flibanserin. The answer is an unambiguous no, and the prohibition extends beyond social drinking.

The ADDYI REMS program requires prescribers to counsel patients that alcohol must be avoided during the entire course of flibanserin therapy. [1] The FDA's own Drug Safety Communication from 2015 reiterated that no safe level of alcohol has been established with flibanserin. [9] This has direct pre-operative relevance because standard pre-operative instructions to "avoid food and drink after midnight" do not always specify alcohol separately, and patients may not connect their REMS counseling to the surgical context.

Pre-operative nursing intake should include the question: "Do you take Addyi (flibanserin)?" as a distinct item, separate from general CNS depressant screening. The interaction severity is Black Box level, which by FDA classification standards means it may cause serious injury or death. [1]

Special Populations and Considerations

Patients on Hormonal Therapy

Many patients taking flibanserin for hypoactive sexual desire disorder (HSDD) are also receiving hormonal therapy. Estrogen-containing oral contraceptives are moderate CYP3A4 inhibitors and increased flibanserin AUC by 2.3-fold in a dedicated pharmacokinetic study. [1] A woman arriving for surgery on both an oral contraceptive and flibanserin may have higher-than-expected flibanserin concentrations even at two days post-last-dose. Hormone therapy use should be captured at pre-operative assessment.

Patients With Hepatic Impairment

Flibanserin is contraindicated in patients with any degree of hepatic impairment per the FDA label because hepatic metabolism is the primary clearance route. [1] Anesthesiologists managing patients with cirrhosis or elevated liver enzymes should be aware that if flibanserin was prescribed off-label or without appropriate screening, residual drug concentrations may be disproportionately elevated and the washout period may need extension. Hepatic CYP3A4 activity correlates with Child-Pugh class; Child-Pugh B and C patients clear CYP3A4 substrates 2 to 4 times more slowly. [10]

Elderly Patients

The approved indication for flibanserin is premenopausal women; clinical trial data in postmenopausal or elderly populations are limited. [1] Off-label use in older patients is reported clinically, and older adults have reduced CYP3A4 activity, lower albumin binding, and decreased cardiac output, all of which extend effective drug exposure. Standard two-day washout may be insufficient in women over 65 receiving flibanserin off-label.

Urgent and Emergency Surgery Without Washout

Not every surgery is elective. When a patient taking flibanserin requires urgent or emergent surgery and a two-day washout is not possible, the anesthetic plan must account for pharmacologically active drug.

Published anesthesiology pharmacology reviews on CNS-active drug interactions support the following principles for non-washout cases. [11] First, regional anesthesia should be considered as the primary technique where surgical site allows, since spinal or epidural anesthesia minimizes the CNS depressant burden, though spinal-induced vasodilation still requires careful fluid and vasopressor management. Second, total intravenous anesthesia (TIVA) with propofol and remifentanil allows more precise titration than volatile agents and may reduce cumulative hypotensive load. Third, continuous invasive arterial pressure monitoring is appropriate for ASA class II or higher patients with active flibanserin exposure. [12]

The anesthesiologist should document the known flibanserin exposure, the rationale for proceeding without full washout, and the specific hemodynamic management plan in the pre-anesthetic note.

Post-operative Pain Management Adjustments

Opioid analgesics remain the backbone of moderate-to-severe post-operative pain management. In patients with residual flibanserin, multimodal analgesia that reduces opioid requirements is preferable. [6]

Scheduled acetaminophen 1,000 mg every 6 hours reduces opioid consumption by approximately 20 to 30% in post-surgical patients across multiple meta-analyses. [13] Ketorolac 15 to 30 mg IV reduces opioid requirements by a comparable margin in eligible patients. [13] Nerve blocks or wound infiltration with long-acting local anesthetics (liposomal bupivacaine) provide site-specific analgesia without the cardiovascular interaction profile of systemic opioids.

If opioids are unavoidable, the nursing team should be alerted to the potential for augmented sedation and hypotension, and pulse oximetry monitoring should continue for at least two hours after each dose in the first 24 post-operative hours.